Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models

Human Gene Therapy

Volumn 10, Issue 5, 1999, Pages 697-709

  Emtage, P C R ^a   Wan, Y ^a   Hitt, M ^a   Graham, F L ^a   Muller, W J ^a   Zlotnik, A ^b   Gauldie, J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOTACTIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; GENE THERAPY; IMMUNE RESPONSE; INTRATUMORAL DRUG ADMINISTRATION; LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR REGRESSION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CHEMOKINES, C; CYTOTOXICITY TESTS, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOKINES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MODELS, GENETIC; SIALOGLYCOPROTEINS; TIME FACTORS;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0033586324     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018463     Document Type: Article

References (55)

1. ADDISON, C.L., BRACIAK, T., RALSTON, R., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1995a). Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. U.S.A. 92, 8522-8526.
2. ADDISON, C.L., GAULDIE, J., MULLER, W.J., and GRAHAM, F.L. (1995b). An adenovirus vector expressing interleukin-4 modulates tumorigenicity and induces tumor regression in a murine breast cancer model. Int. J. Oncol. 7, 1253-1259.
3. ADDISON, C.L., BRAMSON, J.L., HITT, M.M., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1998). Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 5, 1400-1409.
4. AZUMA, M., ITO, D., YAGITA, H., OKUMURA, K., PHILLIPS, J.H., LANIER, L.L., and SOMOZA, C. (1993). B70 antigen is a second ligand for CTLA-4 and CD28. Nature (London) 366, 76-79.
5. BAGGIOLINI, M., DEWALD, B., and MOSER, B. (1997). Human chemokines: An update. Annu. Rev. Immunol. 15, 675-705.
6. BASKAR, S., GLIMCHER, L., NABAVI, N., JONES, R.T., and OSTRAND-ROSENBERG, S. (1995). Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619-629.
7. BETT, A.J., HADDARA, W., PREVEC, L., and GRAHAM, F.L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U.S.A. 91, 8802-8806.
8. BIANCHI, G., SOZZANI, S., ZLOTNIK, A., MANTOVANI, A., and ALLAVENA, P. (1996). Migratory response of human natural killer cells to lymphotactin. Eur. J. Immunol. 26, 3238-3241.
9. BOISMENU, R., FENG, L., XIA, Y.Y., CHANG, J.C., and HAVRAN, W.L. (1996). Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. J. Immunol. 157, 985-992.
10. BRAMSON, J.L., HITT, M., ADDISON, C.L., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1996). Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7, 1995-2002.
11. CAYEUX, S., BECK, C., AICHER, A., DORKEN, B., and BLANKENSTEIN, T. (1995). Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating lymphocytes and are strong vaccines. Eur. J. Immunol. 25, 2325-2331.
12. CHEN, L., ASHE, S., BRADY, W.A., HELSTROM, I., HELSTROM, K.E., LEDBETTER, J.A., McGOWAN, P., and LINSLEY, P.S. (1992). Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
13. DILLOO, D., BACON, K., HOLDEN, W., ZHONG, W., BURDACH, S. ZLOTNIK, A., and BRENNER, M. (1996). Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Med. 2, 1090-1095.
14. DORNER, B., MULLER, S., ENTSCHLADEN, F., SCHRODER, J.M., FRANKE, P., KRAFT, R., FRIEDL, P., CLARK-LEWIS, L., and KROCZEK, R.A. (1996). Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8(+) T cells. J. Biol. Chem. 272, 8817-8823.
15. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
16. EMTAGE, P.C.R., WAN, Y., BRAMSON, J.L., GRAHAM, F.L., and GAULDIE, J. (1998). A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J. Immunol. 160, 2531-2538.
17. FOREMAN, N.K., RILL, D.R., COUSTAN-SMITH, E., DOUGLASS, B.C., and BRENNER, M.K. (1993). Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br. J. Cancer 67, 933-938.
18. FREEMAN, G.J., GRAY, G.S., GIMMI, C.D., LOMBARD, D.B., ZHOU, L.J., WHITE, M., FINGEROTH, J.D., GRIBBEN, J.G., and NADLER, L.M. (1991). Structure, expression and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174, 625-631.
19. FREEMAN, G.J., BORRIELLO, F., HODES, R.J., REISER, H., GRIBBEN, J.G., NG, J.W., KIM, J., GOLDBERG, J.M., HATHCOCK, K., and LASZLO, G. (1993a). Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178, 2185-2192.
20. FREEMAN, G.J., GRIBBEN, J.G., BOUSSIOTIS, V.A., NG, J.W., RESTIVO, V.A., LOMBARD, L.A., GRAY, G.S., and NADLER, L.M. (1993b). Cloning of B7-2: A CTLA-4 counter-receptor that costimualtes human T cell proliferation. Science 262, 909-911.
21. GRAHAM, F.L. (1987). Growth of 293 cells in suspension culture. J. Gen. Virol. 68, 937-940.
22. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
23. GUY, C.T., CARDIFF, R.D., and MULLER, W.J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954-961.
24. HEDRICK, J.A., SAYLOR, V., FIGUEROA, D., MIZOUE, L., XU, Y., MENON, S., ABRAMS, J., HANDEL, T., and ZLOTNIK, A. (1997). Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J. Immunol. 158, 1533-1540.
25. HIROSE, K., HAKOZAKI, M., NYUNOYA, Y., KOBAYASHI, Y., MATSUSHITA, K., TAKENOUCHI, T., MIKATA, A., MUKAIDA, N., and MATSUSHIMA, K. (1995). Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br. J. Cancer 72, 708-714.
26. HUANG, S., XIE, K., SINGH, R.K., GUTMAN, M., and BAR-ELI, M. (1996). Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J. Interferon Cytokine Res. 15, 655-665.
27. JANG, S.K., KRAUSSLICH, H.G., NICKLIN, M.J., DUKE, G.M., PALMENBERG, A.C., and WIMMER, E. (1988). A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62, 3636-3643.
28. KELNER, G.S., KENNEDY, J., BACON, K.B., KLEYENSTEUBER, S., LARGAESPADA, D.A., JENKINS, N.A., COPELAND, N.G., BAZAN, J.F., MOORE, K.W., SCHALL, T.J., and ZLOTNIK, A. (1994). Lymphotactin: A cytokine that represents a new class of chemokine. Science 266, 1395-1399.
29. KENNEDY, J., KELNER, G.S., KLEYENSTEUBER, S., SCHALL, T.J., WEISS, M.C., YSSEL, H., SCHNEIDER, P.V., COCKS, B.G., BACON, K.B., and ZLOTNIK, A. (1995). Molecular cloning and functional characterization of human lymphotactin. J. Immunol. 155, 203-209.
30. LA MOTTE, R.N., RUBIN, M.A., BARR, E., LEIDEN, J.M., BLUESTONE, J.A., and MOKYR, M.B. (1996). Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42, 161-169.
31. LANING, J., KAWASAKI, H., TANAKA, E., LUO, Y., and DORF, M.E. (1994). Inhibition of in vivo tumor growth by the beta chemokine, TCA3. J. Immunol. 153, 4625-4635.
32. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153, 421-428.
33. MAGHAZACHI, A.A., SKALHEGG, B.S., ROLSTAD, B., and ALAOUKATY, A. (1997). Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins. FASEB J. 11, 765-774.
34. MATULONIS, U.A., DOSIOU, C., LAMONT, C., FREEMAN, G.J., MAUCH, P., NADLER, L.M., and GRIFFIN, J.D. (1995). Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85, 2507-2515.
35. MULE, J.J., CUSTER, M., AVERBOOK, B., YANG, J.C., WEBER, J.S., GOEDDEL, D.V., ROSENBERG, S.A., and SCHALL, T.J. (1996). RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations. Hum. Gene Ther. 7, 1545-1553.
36. + T lymphocytes. Eur. J. Immunol. 25, 1744-1748.
37. NABEL, G.J., NABEL, E.G., YANG, Z.Y., FOX, B.A., PLAUTZ, G.E., GAO, X., HUANG, L., SHU, S., GORDON, D., and CHANG, A.E. (1993). Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. U.S.A. 90, 11307-11311.
38. PUTZER, B.M., HITT, M., MULLER, W.J., EMTAGE, P., GAULDIE, J., and GRAHAM, F.L. (1997). Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. U.S.A. 94, 10889-10894.
39. PUTZER, B.M., BRAMSON, J.L., ADDISON, C.L., HITT, M., SIEGEL, P.M., MULLER, W.J., and GRAHAM, F.L. (1998). Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum. Gene Ther. 9, 707-718.
40. RAMARATHINAM, L., CASTLE, M., WU, Y., and LIU, Y. (1994). T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179, 1205-1214.
41. ROLLINS, B.J. (1997). Chemokines. Blood 90, 909-928.
42. ROSENBERG, S.A., LOTZE, M.T., MUUL, L.M., LEITMAN, S., CHANG, A.E., ETTINGHAUSEN, S.E., MATORY, Y.L., SKIBBERY, J.M., SHILONI, E., VETTO, J.T., SEIPP, C.A., SIMPSON, C., and REICHERT, C.M. (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with cancer. N. Engl. J. Med. 313, 1485-1492.
43. ROSENBERG, S.A., PACKARD, B.S., AEBERSOLD, P.M., TOPALIAN, S.L., TOY, S.T., SIMON, P., LOTZE, M.T., YANG, J.C., SEIPP, C.A., SIMPSON, C., CARTER, C., BOCK, S., SCHWARTZENTRUBER, D., WEI, J.P., and WHITE, D.E. (1988). Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676-1680.
44. ROSENBERG, S.A., LOTZE, M.T., YANG, J.C., AEBERSOLD, P.M., LINEHAN, W.M., SEIPP, C.A., and WHITE, D.E. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 patients. Ann. Surg. 210, 474-484.
45. RUMSAENG, V., VLIAGOFTIS, H., OH, C.K., and METCALFE, D.D. (1997). Lymphotactin gene expression in mast cells following Fc(epsilon) receptor I aggregation: Modulation by TGF-beta, IL-4, dexamethasone, and cyclosporin A. J. Immunol. 158, 1353-1360.
46. SALVADORI, S., GANSBACHER, B., WERNICK, I., TIRELLI, S., and ZIER, K. (1995). B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naïve cells in vitro. Hum. Gene Ther. 6, 1299-1306.
47. SCHALL, T.J., BACON, K., CAMP, R.D., KASPARI, J.W., and GOEDDEL, D.V. (1993). Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J. Exp. Med. 177, 1821-1826.
48. SIEGEL, P.M., and MULLER, W.J. (1996). Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc. Natl. Acad. Sci. U.S.A. 93, 8878-8883.
49. SIEGEL, P.M., DANKORT, D.L., HARDY, W.R., and MULLER, W.J. (1994). Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14, 7068-7077.
50. STRIETER, R.M., POLVERINI, P.J., ARENBERG, D.A., WALZ, A., OPDENAKKER, G., VAN DAMME, J., and KUNKEL, S.L. (1995). Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukocyte Biol. 57, 752-762.
51. TAHARA, H., ZEH, H.J., STORKUS, W.J., PAPPO, I., WATKINS, S.C., GUBLER, U., WOLF, S.F., ROBBINS, P.D., and LOTZE, M.T. (1994). Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54, 182-189.
52. + T cells by B7-transfected melanoma cells. Science 259, 368-370.
53. TOWNSEND, S.E., SU, F.W., ATHERTON, J.M., and ALLISON, J.P. (1994). Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer REs. 54, 6477-6483.
54. YANG, G., HELLSTROM, K.E., HELLSTROM, I., and CHEN, L. (1995). Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800.
55. ZITVOGEL, J., ROBBINS, P.D., STORKUS, W.J., CLARKE, M.R., MAEURER, M.J., CAMPBELL, R.L., DAVIS, C.G., TAHARA, H., SCHREIBER, R.D., and LOTZE, M.T. (1996). Interleukin-12 and B7.1 costimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 26, 1335-1341.